{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:36:12Z","timestamp":1781649372090,"version":"3.54.5"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inavolisib, a recently approved phosphatidylinositol 3-kinase \u03b1 (PI3K\u03b1) inhibitor for advanced breast cancer, carries a notable risk of hyperglycemia. Despite this established, on-target adverse effect, clinical endocrinologists often lack sufficient awareness regarding both the risk profile and the specific management strategies required for Inavolisib-induced hyperglycemia. The objective of this report is to describe a patient with fulminant-like diabetes accompanied by Hyperosmolar Hyperglycemic State (HHS) following Inavolisib administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 59-year-old female patient with metastatic breast cancer developed rapid-onset and severe hyperglycemia (blood glucose: 48.0 mmol\/L at emergency presentation) progressing to HHS within 72 hours of initiating Inavolisib therapy. She presented with fatigue but showed no evidence of ketoacidosis. She had no personal or family history of diabetes mellitus and multiple prior random blood glucose measurements were within normal range. Admission laboratory findings included glycated hemoglobin A1c (HbA1c) 5.7%\u00a0(reference: 4.0-6.0%), fasting plasma glucose 8.6 mmol\/L, fasting insulin 41.5 \u03bcU\/mL (reference: 2.6\u201324.9 \u03bcU\/mL), and fasting C-peptide 10.2 ng\/mL (reference: 1.1\u20134.4 ng\/mL), Diabetes-related autoantibodies (ICA, GADA, IAA) were negative. After discontinuation of Inavolisib and administration of intensive insulin therapy, the patient\u2019s hyperglycemia resolved rapidly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inavolisib-induced hyperglycemia may occur abruptly after treatment initiation and can rapidly progress to severe hyperglycemic emergencies such as HHS, even in patients without known dysglycemia. Normal baseline glycemic indices do not reliably exclude the risk of severe toxicity. Early metabolic assessment, close glucose monitoring, prompt interruption of inavolisib when clinically indicated, and rapid insulin-based management are essential for timely recognition and safe clinical care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1747317","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:47:28Z","timestamp":1778215648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Inavolisib-induced fulminant-like diabetes and hyperosmolar hyperglycemic state: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongyu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxiang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11912-019-0846-7","article-title":"PI3K inhibitors in breast cancer therapy","volume":"21","author":"Ellis","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00838-2","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071598","article-title":"Management strategies for hyperglycemia associated with the \u03b1-selective PI3K inhibitor alpelisib for the treatment of breast cancer","volume":"14","author":"Tankova","year":"2022","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02136-y","article-title":"Inavolisib: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/COC.0000000000001209","article-title":"Inavolisib for HR-positive, HER2-negative advanced breast cancer: Clinical trials and patient access implication","volume":"48","author":"Arabshomali","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"x3","DOI":"10.1093\/annonc\/mdz281","article-title":"Overview of the relevance of PI3K pathway in HR-positive breast cancer","volume":"30","author":"Vasan","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer","volume":"22","author":"Mart\u00ednez-S\u00e1ez","year":"2020","journal-title":"Breast Cancer Res BCR"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162508","article-title":"PI3K\/AKT\/mTOR-targeted therapy for breast cancer","volume":"11","author":"Zhu","year":"2022","journal-title":"Cells"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.08.003","article-title":"Cancer-associated PIK3CA mutations in overgrowth disorders","volume":"24","author":"Madsen","year":"2018","journal-title":"Trends Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1539","article-title":"Integrative\u00a0survival-based molecular profiling of human pancreatic cancer","volume":"18","author":"Donahue","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: Variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2024.2415103","article-title":"Preclinical assessment of the PI3K\u03b1 selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human","volume":"54","author":"Salphati","year":"2024","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/15347354211073163","article-title":"Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia","volume":"21","author":"Goncalves","year":"2022","journal-title":"Integr Cancer Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00110","article-title":"Phase I\/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA-mutated, hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced or metastatic breast cancer","volume":"42","author":"Jhaveri","year":"2024","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00673-9","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2024.100294","article-title":"Alpelisib (phosphatidylinositol 3-kinase inhibitor) induced uncontrolled hyperglycemia and\u00a0colitis","volume":"14","author":"Duhan","year":"2024","journal-title":"Curr Probl Cancer Case Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2019.02.002","article-title":"PIK3CA in cancer: The past 30 years","volume":"59","author":"Arafeh","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2022.115","article-title":"ALPELISIB - INDUCED HYPERGLYCEMIA","volume":"18","author":"Ekanayake","year":"2022","journal-title":"Acta Endocrinol Buchar Rom 2005"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05668-1","article-title":"Serum osmolality and hyperosmolar states","volume":"38","author":"B\u00fcy\u00fckkarag\u00f6z","year":"2023","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf422","article-title":"Hyperglycemic hypernatremic hypertonic state: A predominant HHS subtype and its clinical and diagnostic features","volume":"111","author":"Cao","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1530\/EDM-24-0040","article-title":"Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition","volume":"2024","author":"Sriravindrarajah","year":"2024","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4579","article-title":"Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.8504","article-title":"Evaluation of type 2 diabetic mellitus animal models via interactions between insulin and mitogen-activated protein kinase signaling pathways induced by a high fat and sugar diet and streptozotocin","volume":"17","author":"Zhuo","year":"2018","journal-title":"Mol Med Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2024.09.017","article-title":"Effective strategies for the prevention and mitigation of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia: Optimizing patient care","volume":"25","author":"Moore","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/23247096221105249","article-title":"S.U.G.A.R: A case to outline tactics for the prevention of alpelisib-induced hyperglycemia","volume":"10","author":"Thomas","year":"2022","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1236","article-title":"Fulminant type 1 diabetes\u2014an important subtype in East Asia","volume":"27","author":"Imagawa","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115397","article-title":"Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1\/1b study","volume":"221","author":"Bedard","year":"2025","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15005","article-title":"Management of hyperosmolar hyperglycaemic state (HHS) in adults: An updated guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care Group","volume":"40","author":"Mustafa","year":"2023","journal-title":"Diabetes Med J Br Diabetes Assoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13406","article-title":"ISPAD\u00a0clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state","volume":"23","author":"Glaser","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-24-0040","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5492\/wjccm.v12.i1.29","article-title":"Severe hypernatremia in hyperglycemic conditions; managing it effectively: A case report","volume":"12","author":"Lathiya","year":"2023","journal-title":"World J Crit Care Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01422","article-title":"Discovery of GDC-0077 (inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1","volume":"65","author":"Hanan","year":"2022","journal-title":"J\u00a0Med Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30721","article-title":"Efficacy and safety of intravenous insulin in treatment of patient with diabetic ketoacidosis: A systematic review and meta-analysis","volume":"14","author":"Alshurtan","year":"2022","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.016","article-title":"Clinically approved monoclonal antibodies-based immunotherapy: Association with glycemic control and impact role of clinical pharmacist for cancer patient care","volume":"46","author":"Al-Taie","year":"2024","journal-title":"Clin Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2021-2592","article-title":"Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Am J Cancer Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1747317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:47:33Z","timestamp":1778215653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1747317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":40,"alternative-id":["10.3389\/fendo.2026.1747317"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1747317","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1747317"}}